Zimmer Biomet (NYSE:ZBH) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Zimmer Biomet (NYSE:ZBH) from a buy rating to a hold rating in a research note issued to investors on Saturday.

ZBH has been the topic of several other reports. Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a report on Wednesday, November 5th. Finally, BTIG Research reissued a “buy” rating and issued a $112.00 target price on shares of Zimmer Biomet in a report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Trading Up 1.2%

NYSE:ZBH opened at $96.32 on Friday. Zimmer Biomet has a 12-month low of $84.59 and a 12-month high of $114.44. The firm has a market cap of $19.09 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 1.97 and a beta of 0.62. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The stock has a fifty day moving average price of $90.17 and a 200 day moving average price of $95.69.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds have recently made changes to their positions in the business. Key Financial Inc grew its position in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. boosted its position in Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 116 shares during the last quarter. Root Financial Partners LLC acquired a new stake in shares of Zimmer Biomet during the third quarter valued at about $31,000. Cary Street Partners Investment Advisory LLC boosted its holdings in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. Finally, Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet during the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.